The role of the CEO is subordinate to the board of directors and the CEOs’ main task is to carry out the Company’s ongoing management and the daily activities of the Company. The rules of procedure of the board of directors and the instructions for the CEO stipulate which matters the board shall resolve upon, and which matters fall within the CEOs’ area of responsibility.

Furthermore, the CEO is responsible for preparing reports and necessary information for decision-making prior to board meetings and presents the material at board meetings.

The senior management currently consists of the CEO, CFO, Head of Regulatory Affairs, Head of Clinical Development, Head of Research and CMC, CMO, CSO, CCO, Head of Medical Relations, Head of IR and Head of Pharmacovigilance.

Name Position Member of senior management since Employed in the Company since Holdings in Oncopeptides (1)
Jakob Lindberg CEO 2011 2011 235,409 1,070 250,050
Anders Martin-Löf CFO 2018 2018 3,000 212,118
Bengt Gustavsson Head of Medical Relations 2017 2017 600 116,995
Christian Jacques CSO 2018 2018 (2) 223,280
Elisabeth Augustsson Head of Regulatory Affairs 2015 2015 (2) 93,117
Eva Nordström Head of Clinical Development 2012 2012 150,200 33 117,283
Fredrik Lehmann Head of Research and CMC 2008 2008 1,000 50 82,017
Johan Harmenberg CMO 2012 2012 (2) 5,000 160 82,806
Paula Boultbee CCO 2016 2016 124,445
Rein Piir Head of IR 2016 2016 (2) 2,500 89,917
Thomas Bradley Head of Pharmacovigilance 2017 2018 (2) 70,387
(1) Refers to shares (“SH”), employee options (“EO”) and options (“O”) held in their own name as well as by affiliated natural and legal persons. Employee options that are vested in accordance with prevailing terms and conditions each entitle to the subscription of 900 shares per option in Company. The options (“O”) entitles to one share per option in accordance with existing terms. For terms, please read under Corporate Governance – Remuneration.
(2) The assignment is carried out on a consultancy basis.